{"Clinical Trial ID": "NCT00418028", "Intervention": ["INTERVENTION 1:", "Army A (Cint)", "Capecitabine will be administered orally at a dose of 1250 mg/m2 twice daily (in the morning and evening, equivalent to a total daily dose of 2500 mg/m2) for 14 days, in three weekly cycles with a rest period of 7 days, until disease progression or severe toxicity.", "INTERVENTION 2:", "Bras B (Cont)", "- Capecitabine 800 mg/m2 orally twice daily (in the morning and evening the equivalent of a dose of 1600 mg/m2) for 21 days, for 3 weeks without rest period, until disease progression or severe toxicity."], "Eligibility": ["\u2022 Inclusion criteria", "Patients with metastatic breast cancer", "Patients who have received or have not received prior treatment with anthracyclines and/or taxanes (either in advance or in metastatic disease).", "The patient is outpatient with functional ECOG status < 2 (see Appendix 2).", "The patient has at least one measurable injury according to the RECIST criteria (see Appendix 3)", "* Patients with a life expectancy of at least 3 months.", "Patients who accept and are able to meet the requirements of the entire protocol throughout the study.", "- Exclusion criteria:", "Patients who have previously experienced unexpected severe reactions to fluoropyrimidine therapy or who have known sensitivity to 5-fluorouracil.", "Patients previously treated with capecitabine.", "\u2022 Patients who have undergone organ transplants.", "Other serious diseases or conditions:", "Patients with previous seizures, central nervous system diseases or psychiatric diseases, including dementia, that the investigator may consider clinically significant and negatively affect therapeutic compliance.", "* Patients with severe intellectual impairment, unable to perform basic daily routines and established depression.", "A major clinical heart disease (e.g. congestive heart failure, symptomatic coronary disease and cardiac arrhythmia not fully controlled by medicines) or myocardial infarction in the past 12 months.", "Severe renal impairment (basic creatinine clearance < 30 ml/min)", "Patients with a history of uncontrolled seizures, central nervous system disorders or psychiatric incapacity considered clinically significant by the investigator, who exclude informed consent or interfere with compliance with oral drug use, should be excluded.", "Patients with active infection.", "Patients with a history of neoplasia in the last five years, except for skin cancer of basal cells or cervical cancer in situ, both cured.", "In patients with the following biological values:", "Number of neutrophils < 555 x 109/l", "Number of platelets < 100 x 109/l", "Serum creatinine > 1.5 x upper limit of normality", "Serum bilirubin > 2.0 x upper limit of normality", "ALT, AST > 2.5 x upper limit of normality or > 5 x upper limit of normality for liver metastases", "In the case of liver metastases, the upper limit of normality may be greater than 5 x in the case of bone metastases.", "Patients on radiotherapy four weeks prior to the start of treatment of the study, or on previous radiotherapy of marker lesions, should be measured during the study (new marker lesions that appear in previously irradiated areas are accepted) or patients receiving scheduled radiation therapy.", "Patients on major surgery within 4 weeks prior to study treatment or who have not fully recovered the effects of major surgery.", "Patients who do not have the physical integrity of the upper gastrointestinal tract or suffer from malabsorption syndrome.", "Patients who have received more than two cycles of chemotherapy for metastatic disease.", "\u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022 \u2022"], "Results": ["Performance measures:", "\u266a It's time to move on \u266a", "The progression time (TPT) is defined as the time (in months) between the time the patient begins treatment for the study and the date of the progressive disease, i.e., a patient has an event that is that he or she is progressing or dying as a result of a progressive disease.", "Time limit: After 1 year from the date of start of treatment.", "Results 1:", "Title of arm/group: Arm A (Cint)", "Description of the arm/group: Capecitabine should be administered orally at a dose of 1250 mg/m2 twice daily (in the morning and evening, equivalent to a total daily dose of 2500 mg/m2) for 14 days, in 3 weekly cycles with a rest period of 7 days, until disease progression or severe toxicity.", "Total number of participants analysed: 72", "Median (95% confidence interval)", "Unit of measure: month 8.68 (6.55 to 11.05)", "Results 2:", "Title of arm/group: Arm B (Contains)", "Description of the arm/group: Capecitabine 800 mg/m2 orally twice daily (in the morning and evening the equivalent of a dose of 1600 mg/m2) for 21 days, in 3 weeks without rest period, until disease progression or severe toxicity.", "Total number of participants analysed: 84", "Median (95% confidence interval)", "Unit of measure: months 6.84 (6.02 to 8.06)"], "Adverse Events": ["Undesirable Events 1:", "Total: 13/95 (13.68 per cent)", "- Neutrophils/granulocytes (ANC/AGC)1/95 (1.05%)", "Ventricular arrhythmia1/95 (1.05%)", "Diarrhoea6/95 (6.32%)", "Obstruction1/95 (1.05%)", "- Mucositis/stomatitis1/95 (1.05%)", "- Febrile neutropenia2/95 (2.11 %)", "Infection with unknown CNA0/95 (0.00 %)", "Dizzying sensations1/95 (1.05%)", "Renal impairment0/95 (0.00 %)", "Adverse Events 2:", "Total: 4/97 (4.12 per cent)", "- Neutrophils/granulocytes (ANC/AGC)1/97 (1.03%)", "- Ventricular arrhythmia0/97 (0.00%)", "Diarrhoea0/97 (0.00 %)", "- Obstruction/97 (0.00 %)", "- Mucositis/stomatitis0/97 (0.00 %)", "Febrile neutropenia0/97 (0.00 %)", "Infection with unknown CNA1/97 (1.03%)", "- Dizzying sensations/97 (0.00 %)", "Renal impairment1/97 (1.03%)"]}